Open an account

Fulgent Genetics

FLGT · NASDAQ

$20.33+$0.23 (+1.14%)TodayMarket closed ·
Prev close $20.10

About FLGT

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in El Monte, California and currently employs 1,315 full-time employees. The company went IPO on 2016-09-28. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

Employees
1,315
Headquarters
El Monte, California
Listed
Sep 28, 2016
Sector
Health Care
Industry
Health Care Providers & Services
Website
fulgentgenetics.com

FLGT key statistics

Market cap
559.39M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
289.30K
Volume
161.02K
Open price
$20.19
High today
$20.67
Low today
$19.96
52 Week high
$31.04
52 Week low
$13.46

Fulgent Genetics (FLGT) at a glance

Fulgent Genetics (FLGT) last traded at $20.33, with a market cap of 559.39M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $19.96 and $20.67. The current price is 1.9% above the day's low and 1.6% below its high.

Volume so far is 161.02K shares, below the average of 289.30K shares a day.

Over the past year Fulgent Genetics has ranged from $13.46 to $31.04, and now sits 39% of the way up that range.

Fulgent Genetics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.58 per share against an estimate of -$0.4692.

The average analyst price target is $19.38, 4.7% below the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 1 analyst rating say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 3 analystsAvg $19.38
Low
$19.19
Now
$20.33
High
$19.95

FLGT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 170.0% on average.

  1. Q3 FY24: reported $0.31 per share against an estimate of -$0.1564
  2. Q4 FY24: reported $0.04 per share against an estimate of -$0.1258
  3. Q1 FY25: reported $0.04 per share against an estimate of -$0.1887
  4. Q2 FY25: reported $0.07 per share against an estimate of -$0.187
  5. Q3 FY25: reported $0.14 per share against an estimate of -$0.2278
  6. Q4 FY25: reported -$0.36 per share against an estimate of -$0.1071
  7. Q1 FY26: reported -$0.36 per share against an estimate of -$0.1071
  8. Q2 FY26: reported -$0.58 per share against an estimate of -$0.4692

FLGT news

  • Press releaseBusiness Wire

    Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Press releaseBusiness Wire

    Fulgent Reports Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

  • Press releaseBusiness Wire

    Fulgent Presents Updated FID-007 Data at ASCO 2026

  • Press releaseBusiness Wire

    Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

  • Press releaseBusiness Wire

    Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics

  • Press releaseBusiness Wire

    Fulgent Reports First Quarter 2026 Financial Results

Similar companies

Companies in the same industry as Fulgent Genetics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.